Directorio

Before starting treatment, patients will have tests and check-ups for up to 4 weeks. Then, treatment happens in cycles that last 6 weeks. Most people will have up to six cycles. After treatment, doctors will check on patients for about 3 years with visits every 12 weeks. Some early visits may take a long time, up to 6 to 12 hours. There are different groups in the study: - Doublet group: Gets two medicines (AMO959 and AAA617). - Triplet group: Gets three medicines (AMO959, AAA617, and ARPI). - Food-effect group: Tests how food changes AMO959 levels. In each cycle, AAA617 is given on Day 1. AMO959 is taken twice a day from Day 2 to Day 15. The triplet group also takes ARPI every day. The study is open-label, which means you and the doctors know which treatment you are getting. Patients will have regular visits, blood and urine tests, heart checks (ECGs), and scans like CT, MRI, bone scans, and PSMA-PET.

We are doing this study to find out if an experimental drug called eplontersen (the study drug) is safe and helpful for people with cardiac amyloidosis. We are enrolling people who previously participated in a clinical trial for this drug called the CardioTTRansform study (ION-682884-CS2).

We are doing this study to find out if an experimental drug called AS 1763 (the study drug) is a safe and effective option patients with B-cell cancers. We also want to know what the maximum, safe dose of the study drug is.

We are doing this study to find the most effective, safe dose of an experimental drug called visugromab (CTL-002 - the study drug). We want to find out how beneficial this drug is when it is used in combination with immunochemotherapy for people with metastatic non-squamous non-small cell lung cancer.

We are doing this study to find out if an experimental drug called CAP-100 (study drug) is a safe and effective treatment for people who have CLL or SLL that is not responding to standard treatments. We also want to know what dose of this study drug works best.

We are doing this study to monitor the health and quality of life of people who participated in clinical trials for GM T cell therapies.

We are doing this study to find out if an experimental cell therapy called NRTX-1001 (the study drug) is a safe and effective treatment for drug-resistant mesial temporal lobe epilepsy (MTLE). We want to know if the study drug can reduce seizures in people who are not getting relief from conventional treatments.